ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
Operating Expenses
ADC Therapeutics SA
Operating Expenses Peer Comparison
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADC Therapeutics SA
NYSE:ADCT
|
Operating Expenses
$-233m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
Operating Expenses
CHf-68.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Operating Expenses
$-593.7m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Operating Expenses
CHf-111.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
|
Idorsia Ltd
SIX:IDIA
|
Operating Expenses
CHf-893.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Operating Expenses
CHf-28.5m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Operating Expenses?
Operating Expenses
-233m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Operating Expenses amounts to -233m USD.
What is ADC Therapeutics SA's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-13%
Over the last year, the Operating Expenses growth was 29%. The average annual Operating Expenses growth rates for ADC Therapeutics SA have been -2% over the past three years , -13% over the past five years .